MK4 for MDS and AML: Molecular Mechanisms, Clinical Trials and Case Reports

MK4 for MDS and AML: Molecular Mechanisms, Clinical Trials and Case Reports

Vitamin K2 MK-4 As Treatment for MDS and AML - A DiscussionПодробнее

Vitamin K2 MK-4 As Treatment for MDS and AML - A Discussion

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical PathwaysПодробнее

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways

AML Treatment Challenges Who, When, and HowПодробнее

AML Treatment Challenges Who, When, and How

2014 Annual Hematology Meeting: MDS, ALL, & AMLПодробнее

2014 Annual Hematology Meeting: MDS, ALL, & AML

Molecular Targets for Personalized Treatment of AML (Acute Myeloid Leukemia)Подробнее

Molecular Targets for Personalized Treatment of AML (Acute Myeloid Leukemia)

MDS - Myeloplastic Syndromes - 2023 Best of Hematology ConferenceПодробнее

MDS - Myeloplastic Syndromes - 2023 Best of Hematology Conference

Molecular Profile of Acute Myeloid Leukemia (AML)Подробнее

Molecular Profile of Acute Myeloid Leukemia (AML)

AML: What to do with your 500-gene mutation reportПодробнее

AML: What to do with your 500-gene mutation report

Precision Medicine in MDS and AMLПодробнее

Precision Medicine in MDS and AML

From MDS to AML: What Every Patient Needs to Know 11/28/17Подробнее

From MDS to AML: What Every Patient Needs to Know 11/28/17

MPN Transformation to MDS and AML: Risk factors, therapy and outcomesПодробнее

MPN Transformation to MDS and AML: Risk factors, therapy and outcomes

Exploring Promising Treatments and Clinical Trials for #AML Patients #MDSПодробнее

Exploring Promising Treatments and Clinical Trials for #AML Patients #MDS

Mechanisms of TET2 Epigenetics in Myeloid Cancers - K HelinПодробнее

Mechanisms of TET2 Epigenetics in Myeloid Cancers - K Helin

MDS/AML Overlap and Novel Therapies with Dr. Naval DaverПодробнее

MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

Updates from ASH 2020: Promising Treatment Advances for MDS and AMLПодробнее

Updates from ASH 2020: Promising Treatment Advances for MDS and AML

Advancing the management of MDS and AML: Novel immune-based approachesПодробнее

Advancing the management of MDS and AML: Novel immune-based approaches

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical TrialsПодробнее

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

New Biomarkers and Prognostic Indicators in Leukemia and MDSПодробнее

New Biomarkers and Prognostic Indicators in Leukemia and MDS